UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Aleskandarany, M. A., Rakha, E. A., Macmillan, R. D., Powe, D. G., Ellis, I. O., & Green, A. R. (2011). MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast Cancer Research and Treatment*, *127*(3), 591–599. https://doi.org/10.1007/s10549-010-1028-3

Althobiti, M., El Ansari, R., Aleskandarany, M., Joseph, C., Toss, M. S., Green, A. R., & Rakha, E. A. (2020a). The prognostic significance of ALDH1A1 expression in early invasive breast cancer. *Histopathology*, *77*(3), 437–448. https://doi.org/10.1111/his.14129

Althobiti, M., El Ansari, R., Aleskandarany, M., Joseph, C., Toss, M. S., Green, A. R., & Rakha, E. A. (2020b). The prognostic significance of ALDH1A1 expression in early invasive breast cancer. *Histopathology*, *77*(3), 437–448. https://doi.org/10.1111/his.14129

American Cancer Society. (2024). *Breast Cancer Facts & Figures 2022–2023*.

Amin, M. B. ., & Edge, S. B. . (2017). *AJCC cancer staging manual*. Springer.

Andrés-Sánchez, N., Fisher, D., & Krasinska, L. (2022). Physiological functions and roles in cancer of the proliferation marker Ki-67. *Journal of Cell Science*, *135*(11). https://doi.org/10.1242/jcs.258932

Angel, E., Muralee, P. C., Mathew, S. S., Bhasy, S. K., Roselin, ., Kumar, V. D., Nasar, A., & Panicker, P. (2024). Comparison of Four Different Scoring Methods for Ki-67 Percentage in Breast Carcinoma: A Cross-sectional Study. *NATIONAL JOURNAL OF LABORATORY MEDICINE*. https://doi.org/10.7860/NJLM/2024/67776.2847

Arafah, M. A., Ouban, A., Ameer, O. Z., & Quek, K. J. (2021a). KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. *Breast Cancer: Basic and Clinical Research*, *15*. https://doi.org/10.1177/11782234211016977

Arzanova, E., & Mayrovitz, H. N. (2022). The Epidemiology of Breast Cancer. In *Breast Cancer* (pp. 1–20). Exon Publications. https://doi.org/10.36255/exon-publications-breast-cancer-epidemiology

Azoury, F., Misra, S., Barry, A., & Helou, J. (2022). Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review. *Precision Cancer Medicine*, *5*, 3–3. https://doi.org/10.21037/pcm-21-9

Bantis, L. E., Nakas, C. T., & Reiser, B. (2014). Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. *Biometrics*, *70*(1), 212–223. https://doi.org/10.1111/biom.12107

Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018). Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. *Annals of Oncology*, *29*(4), 895–902. https://doi.org/10.1093/annonc/mdy024

Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. *Nature Medicine*, *23*(10), 1124–1134. https://doi.org/10.1038/nm.4409

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016a). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology*, *13*(11), 674–690. https://doi.org/10.1038/nrclinonc.2016.66

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016b). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology*, *13*(11), 674–690. https://doi.org/10.1038/nrclinonc.2016.66

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Bland, K. I., Chang, H. R., & Copeland, E. M. (2018). Modified Radical Mastectomy and Simple Mastectomy. In *The Breast* (pp. 443-461.e3). Elsevier. https://doi.org/10.1016/B978-0-323-35955-9.00031-3

Bridger, J. M., Kill, I. R., & Lichter, P. (1998). Association of pKi-67 with satellite DNA of the human genome in early G1 cells. *Chromosome Research*, *6*(1), 13–24. https://doi.org/10.1023/A:1009210206855

Brown, M., Assen, F. P., Leithner, A., Abe, J., Schachner, H., Asfour, G., Bago-Horvath, Z., Stein, J. V., Uhrin, P., Sixt, M., & Kerjaschki, D. (2018). Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. *Science*, *359*(6382), 1408–1411. https://doi.org/10.1126/science.aal3662

Cariati, P., Martinez Sahuquillo Rico, A., Ferrari, L., Pampin Ozan, D., Gonzalez Corcóles, C., Arroyo Rodriguez, S., Ferrari, S., & Lara, I. M. (2022). Impact of histological tumor grade on the behavior and prognosis of squamous cell carcinoma of the oral cavity. *Journal of Stomatology, Oral and Maxillofacial Surgery*, *123*(6), e808–e813. https://doi.org/10.1016/j.jormas.2022.07.005

Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüuter, C., Galle, J., & Gerdes, J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. *The Journal of Pathology*, *168*(4), 357–363. https://doi.org/10.1002/path.1711680404

Chen, G., Gu, X., Xue, J., Zhang, X., Yu, X., Zhang, Y., Li, A., Zhao, Y., He, G., Tang, M., Xing, F., Yin, J., Bian, X., Han, Y., Cao, S., Liu, C., Jiang, X., Zhang, K., Xia, Y., … Liu, C. (2023). Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study. *ELife*, *12*. https://doi.org/10.7554/eLife.91737

Chen, Z., & Zhao, Y. (2025). The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs. *Frontiers in Pharmacology*, *15*. https://doi.org/10.3389/fphar.2024.1437022

Cidado, J., Wong, H. Y., Rosen, D. M., Cimino-Mathews, A., Garay, J. P., Fessler, A. G., Rasheed, Z. A., Hicks, J., Cochran, R. L., Croessmann, S., Zabransky, D. J., Mohseni, M., Beaver, J. A., Chu, D., Cravero, K., Christenson, E. S., Medford, A., Mattox, A., De Marzo, A. M., … Park, B. H. (2016). Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. *Oncotarget*, *7*(5), 6281–6293. https://doi.org/10.18632/oncotarget.7057

Conner, S. J., Guarin, J. R., Le, T. T., Fatherree, J. P., Kelley, C., Payne, S. L., Parker, S. R., Bloomer, H., Zhang, C., Salhany, K., McGinn, R. A., Henrich, E., Yui, A., Srinivasan, D., Borges, H., & Oudin, M. J. (2024). Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential. *Breast Cancer Research*, *26*(1), 43. https://doi.org/10.1186/s13058-024-01796-8

Cserni, G., Chmielik, E., Cserni, B., & Tot, T. (2018). The new TNM-based staging of breast cancer. *Virchows Archiv*, *472*(5), 697–703. https://doi.org/10.1007/s00428-018-2301-9

Da Cruz Paula, A., MARQUES, O., SAMPAIO, R., ROSA, A., GARCIA, J., RÊMA, A., DE FÁTIMA FARIA, M., SILVA, P., VIZCAÍNO, R., & LOPES, C. (2016). Characterization of CD44+ALDH1+Ki-67– Cells in Non-malignant and Neoplastic Lesions of the Breast. *Anticancer Research*, *36*(9), 4629–4638. https://doi.org/10.21873/anticanres.11013

da Silva, J. L., Cardoso Nunes, N. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020). Triple negative breast cancer: A thorough review of biomarkers. *Critical Reviews in Oncology/Hematology*, *145*, 102855. https://doi.org/10.1016/j.critrevonc.2019.102855

Dalton, L. W., Pinder, S. E., Elston, C. E., Ellis, I. O., Page, D. L., Dupont, W. D., & Blamey, R. W. (2000). Histologic Grading of Breast Cancer: Linkage of Patient Outcome with Level of Pathologist Agreement. *Modern Pathology*, *13*(7), 730–735. https://doi.org/10.1038/modpathol.3880126

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Demir, H., Dulgar, O., Gulle, B. T., Turna, H., & Ilvan, S. (2018). Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas. *Bosnian Journal of Basic Medical Sciences*, *18*(4), 313–319. https://doi.org/10.17305/bjbms.2018.3094

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007). Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. *Clinical Cancer Research*, *13*(15), 4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045

Dogra, A. K., Prakash, A., Gupta, S., & Gupta, M. (2025). Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review. *European Journal of Breast Health*, *21*(2), 101–114. https://doi.org/10.4274/ejbh.galenos.2025.2024-10-2

Douville, J., Beaulieu, R., & Balicki, D. (2009). ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells. *Stem Cells and Development*, *18*(1), 17–26. https://doi.org/10.1089/scd.2008.0055

Duchrow, M., Schlüter, C., Wohlenberg, C., Flad, H., & Gerdes, J. (1996). Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. *Cell Proliferation*, *29*(1), 1–12. https://doi.org/10.1046/j.1365-2184.1996.d01-2.x

Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010a). Triple-Negative Breast Cancer. *New England Journal of Medicine*, *363*(20), 1938–1948. https://doi.org/10.1056/NEJMra1001389

Gangi, A., Mirocha, J., Leong, T., & Giuliano, A. E. (2014). Triple-Negative Breast Cancer is Not Associated with Increased Likelihood of Nodal Metastases. *Annals of Surgical Oncology*, *21*(13), 4098–4103. https://doi.org/10.1245/s10434-014-3989-7

Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. *Cancer Discovery*, *9*(2), 176–198. https://doi.org/10.1158/2159-8290.CD-18-1177

Geyer, F. C., Pareja, F., Weigelt, B., Rakha, E., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2017). The Spectrum of Triple-Negative Breast Disease. *The American Journal of Pathology*, *187*(10), 2139–2151. https://doi.org/10.1016/j.ajpath.2017.03.016

Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M. S., & Dontu, G. (2007a). ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. *Cell Stem Cell*, *1*(5), 555–567. https://doi.org/10.1016/j.stem.2007.08.014

Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018). Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. *Annals of Surgical Oncology*, *25*(7), 1783–1785. https://doi.org/10.1245/s10434-018-6486-6

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., Bonnefoi, H., Bretel-Morales, D., Burstein, H., Cardoso, F., Castiglione-Gertsch, M., Coates, A. S., Colleoni, M., Costa, A., Curigliano, G., … Wood, W. C. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, *24*(9), 2206–2223. https://doi.org/10.1093/annonc/mdt303

Gonçalves, H., Guerra, M. R., Duarte Cintra, J. R., Fayer, V. A., Brum, I. V., & Bustamante Teixeira, M. T. (2018). Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort. *Clinical Medicine Insights: Oncology*, *12*. https://doi.org/10.1177/1179554918790563

Graciano, N., López, L., Rodriguez, C. A., Montoya, K., González, D. M., Gómez, L. R., Zapata, M. L., & Cortés, J. (2025). Effect of chemotherapy timing in triple-negative breast cancer: a

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

real-world evidence study. *Breast Cancer Research and Treatment*, *212*(2), 225–236. https://doi.org/10.1007/s10549-025-07716-4

Grasset, E. M., Dunworth, M., Sharma, G., Loth, M., Tandurella, J., Cimino-Mathews, A., Gentz, M., Bracht, S., Haynes, M., Fertig, E. J., & Ewald, A. J. (2022). Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. *Science Translational Medicine*, *14*(656). https://doi.org/10.1126/scitranslmed.abn7571

Guresci, S., Aydogdu, O. B., Secen, A. E., & Uzel, B. (2025). Assessing the predictive value of Ki-67 and progesterone receptor algorithms for recurrence and disease-free survival in meningiomas. *Annals of Diagnostic Pathology*, *75*, 152441. https://doi.org/10.1016/j.anndiagpath.2025.152441

Hajizadeh, E., Abdollahi, M., Baghestani, A. R., & Haghighat, S. (2018). Prognostic Cut Point for Breast Cancer Age of Diagnosis. *International Journal of Cancer Management*, *11*(5). https://doi.org/10.5812/ijcm.9291

Halperin, & C., E. (2019). *Perez & Brady's Principles and Practice of Radiation Oncology*. Wolters Kluwer.

Hermansyah, D., Al Anas, M., Chalisaturahmi, K. H., Baitina, M., Arto, K. S., & Pasaribu, E. T. (2025). Correlation of Ki67 expression with estrogen receptor (ER) and progesterone receptor (PR) status in breast cancer. *Medicinski Glasnik*, *22*(2). https://doi.org/10.17392/1941-22-02

Honeth, G., Lombardi, S., Ginestier, C., Hur, M., Marlow, R., Buchupalli, B., Shinomiya, I., Gazinska, P., Bombelli, S., Ramalingam, V., Purushotham, A. D., Pinder, S. E., & Dontu, G. (2014). Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. *Breast Cancer Research*, *16*(3), R52. https://doi.org/10.1186/bcr3663

Houvenaeghel, G., Cohen, M., Classe, J. M., Reyal, F., Mazouni, C., Chopin, N., Martinez, A., Daraï, E., Coutant, C., Colombo, P. E., Gimbergues, P., Chauvet, M. P., Azuar, A. S., Rouzier, R., Tunon de Lara, C., Muracciole, X., Agostini, A., Bannier, M., Charaffe Jauffret, E., … Goncalves, A. (2021a). Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. *ESMO Open*, *6*(6), 100316. https://doi.org/10.1016/j.esmoop.2021.100316

Houvenaeghel, G., Cohen, M., Classe, J. M., Reyal, F., Mazouni, C., Chopin, N., Martinez, A., Daraï, E., Coutant, C., Colombo, P. E., Gimbergues, P., Chauvet, M. P., Azuar, A. S., Rouzier, R., Tunon de Lara, C., Muracciole, X., Agostini, A., Bannier, M., Charaffe Jauffret, E., … Goncalves, A. (2021b). Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. *ESMO Open*, *6*(6), 100316. https://doi.org/10.1016/j.esmoop.2021.100316

Hu, C.-A. A., Baum, C., & Xie, Y. (2025). Cancer Metastasis Through the Lymphatics: Invasion and Dissemination. *Lymphatics*, *3*(3), 17. https://doi.org/10.3390/lymphatics3030017

Huo, W., Du, M., Pan, X., Zhu, X., & Li, Z. (2015). Prognostic value of ALDH1 expression in lung cancer: a meta-analysis. In *Int J Clin Exp Med* (Vol. 8, Number 2). www.ijcem.com/

IARC. (2020a). *Breast cancer*. https://www.iarc.who.int/cancer-type/breast-cancer/?

IARC. (2020b). *Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020*. https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/?

Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Research and Treatment*, *139*(2), 539–552. https://doi.org/10.1007/s10549-013-2560-8

Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease
Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Jain, A., Chellappa, V., & Dharanipragada, K. (2023). Inter-Relationship of Ki-67 and Triple-Negative Breast Cancer. In *Breast Cancer Updates*. IntechOpen. https://doi.org/10.5772/intechopen.109586

Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., Kim, T.-Y., Park, I. A., Noh, D.-Y., Heo, D. S., & Bang, Y.-J. (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Research*, *13*(2), R22. https://doi.org/10.1186/bcr2834

Khoury, T., Ademuyiwa, F. O., Chandraseekhar, R., Jabbour, M., DeLeo, A., Ferrone, S., Wang, Y., & Wang, X. (2012). Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. *Modern Pathology*, *25*(3), 388–397. https://doi.org/10.1038/modpathol.2011.172

Kida, K., Ishikawa, T., Yamada, A., Shimada, K., Narui, K., Sugae, S., Shimizu, D., Tanabe, M., Sasaki, T., Ichikawa, Y., & Endo, I. (2013). Abstract 263: Identification of subgroup of triple negative breast cancer by cancer stem cell markers. *Cancer Research*, *73*(8_Supplement), 263–263. https://doi.org/10.1158/1538-7445.AM2013-263

Kim, J., Byun, S., Kim, M., Shin, K., Kim, D., Lee, H., Kim, T., Kim, Y., Kim, Y., Chang, J., Kim, K., & Lee, S. (2024). Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05). *Journal of Personalized Medicine*, *14*(9), 941. https://doi.org/10.3390/jpm14090941

Land, L. H., Dalton, S. O., Jensen, M.-B., & Ewertz, M. (2012). Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. *Breast Cancer Research and Treatment*, *131*(3), 1013–1020. https://doi.org/10.1007/s10549-011-1819-1

Lee, L., Lin, C., Cheng, N., Tsai, C., Hsueh, C., Fan, K., Wang, H., Hsieh, C., Ng, S., Yeh, C., Lin, C., Tsao, C., Fang, T., Huang, S., Lee, L., Kang, C., Fang, K., Wang, Y., Lin, W., … Liao, C. (2021). Poor tumor differentiation is an independent adverse prognostic variable in patients with locally advanced oral cavity cancer—Comparison with pathological risk factors according to the NCCN guidelines. *Cancer Medicine*, *10*(19), 6627–6641. https://doi.org/10.1002/cam4.4195

Leong, S. P., Pissas, A., Scarato, M., Gallon, F., Pissas, M. H., Amore, M., Wu, M., Faries, M. B., & Lund, A. W. (2022). The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. *Clinical & Experimental Metastasis*, *39*(1), 139–157. https://doi.org/10.1007/s10585-021-10123-w

LI, S., & LI, Q. (2014). Cancer stem cells and tumor metastasis. *International Journal of Oncology*, *44*(6), 1806–1812. https://doi.org/10.3892/ijo.2014.2362

Li, W., Ma, H., Zhang, J., Zhu, L., Wang, C., & Yang, Y. (2017). Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. *Scientific Reports*, *7*(1), 13856. https://doi.org/10.1038/s41598-017-14364-2

Li, X., Xu, Q., Fu, X., & Luo, W. (2014). ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. *BMC Cancer*, *14*(1), 705. https://doi.org/10.1186/1471-2407-14-705

Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022). Recent advances in therapeutic strategies for triple-negative breast cancer. *Journal of Hematology & Oncology*, *15*(1), 121. https://doi.org/10.1186/s13045-022-01341-0

Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. *Journal of Clinical Oncology*, *26*(8), 1275–1281. https://doi.org/10.1200/JCO.2007.14.4147

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Liu, Y., Lv, D., Duan, J., Xu, S., Zhang, J., Yang, X., Zhang, X., Cui, Y., Bian, X., & Yu, S. (2014). ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. *BMC Cancer*, *14*(1), 444. https://doi.org/10.1186/1471-2407-14-444

Ma, F., Li, H., Li, Y., Ding, X., Wang, H., Fan, Y., Lin, C., Qian, H., & Xu, B. (2017a). Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC). *Medicine*, *96*(14), e6561. https://doi.org/10.1097/MD.0000000000006561

Ma, I., & Allan, A. L. (2011). The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells. *Stem Cell Reviews and Reports*, *7*(2), 292–306. https://doi.org/10.1007/s12015-010-9208-4

Mahjabeen, F., & Habbani, S. F. (2025). Molecular Mechanisms of Lymphatic Metastasis in Breast Cancer : An Updated Review. *Cancers*, *17*(13), 1–20. https://doi.org/https://doi.org/10.3390/cancers17132134

Mak, J. K. L., McMurran, C. E., Kuja-Halkola, R., Hall, P., Czene, K., Jylhävä, J., & Hägg, S. (2023). Clinical biomarker-based biological aging and risk of cancer in the UK Biobank. *British Journal of Cancer*, *129*(1), 94–103. https://doi.org/10.1038/s41416-023-02288-w

Malik, M., Ramanan, N., Upneja, S., Brackstone, M., Porter, L., Fifield, B.-A., & Hamm, C. (2024). Abstract PO3-03-09: Clinical Significance of Grade in Triple Negative Breast Cancer. *Cancer Research*, *84*(9_Supplement), PO3-03-09-PO3-03–09. https://doi.org/10.1158/1538-7445.SABCS23-PO3-03-09

Mehta, A., Kumar, D., Chadha, P., Goswami, M., Vishwakarma, G., Panigrahi, M., Suryavanshi, M., & Panaych, A. (2019). Diagnostic ability of real-time quantitative polymerase chain reaction versus immunohistochemistry for Ki-67 assessment in breast cancer. *Indian Journal of Medical Research*, *150*(3), 254–260. https://doi.org/10.4103/ijmr.IJMR_644_18

Miyoshi, Y., Shien, T., Ogiya, A., Ishida, N., Yamazaki, K., Horii, R., Horimoto, Y., Masuda, N., Yasojima, H., Inao, T., Osako, T., Takahashi, M., Tomioka, N., Endo, Y., Hosoda, M., Doihara, H., Miyoshi, S., & Yamashita, H. (2016). Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. *Breast Cancer Research*, *18*(1), 73. https://doi.org/10.1186/s13058-016-0731-3

Morimoto, K., Kim, S. J., Tanei, T., Shimazu, K., Tanji, Y., Taguchi, T., Tamaki, Y., Terada, N., & Noguchi, S. (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. *Cancer Science*, *100*(6), 1062–1068. https://doi.org/10.1111/j.1349-7006.2009.01151.x

Murrja, E., Turna, Z. H., Ozturk, M. A., Cinkaya, A., & Ozturk, T. (2019). Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer. *Medical Science and Discovery*, *1*(2), 44–50. https://doi.org/10.36472/msd.v1i2.28

Na, Y. M., Ryu, Y. J., Cho, J. S., Park, M. H., & Yoon, J. H. (2021). Lymphovascular Invasion as a Predictive Factor for Recurrence in Triple-Negative Breast Cancer. *Indian Journal of Surgery*, *83*(S2), 475–483. https://doi.org/10.1007/s12262-021-02783-5

Nascimento, R. G. do, & Otoni, K. M. (2020). Histological and molecular classification of breast cancer: what do we know? *Mastology*, *30*. https://doi.org/10.29289/25945394202020200024

Nassar, D., & Blanpain, C. (2016). Cancer Stem Cells: Basic Concepts and Therapeutic Implications. *Annual Review of Pathology: Mechanisms of Disease*, *11*(1), 47–76. https://doi.org/10.1146/annurev-pathol-012615-044438

NCCN. (2025). *NCCN Clinical Practice Guidelines in Oncology: Imflamtory Breast Cancer*. National Comprehensive Cancer Network.

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Nguyen, A. L., Facey, C. O. B., & Boman, B. M. (2024). The Significance of Aldehyde Dehydrogenase 1 in Cancers. *International Journal of Molecular Sciences*, *26*(1), 251. https://doi.org/10.3390/ijms26010251

Notoatmodjo. (2012). *Metodologi Penelitian Kesehatan*. Rineka Cipta.

Nwani, N. G., Condello, S., Wang, Y., Swetzig, W. M., Barber, E., Hurley, T., & Matei, D. (2019). A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. *Cancers*, *11*(4), 502. https://doi.org/10.3390/cancers11040502

Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. *Pharmaceutics*, *15*(7), 1796. https://doi.org/10.3390/pharmaceutics15071796

Ohi, Y., Umekita, Y., Yoshioka, T., Souda, M., Rai, Y., Sagara, Y., Sagara, Y., Sagara, Y., & Tanimoto, A. (2011). Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. *Histopathology*, *59*(4), 776–780. https://doi.org/10.1111/j.1365-2559.2011.03884.x

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., & Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *New England Journal of Medicine*, *377*(19), 1836–1846. https://doi.org/10.1056/NEJMoa1701830

Pan, Y., Yuan, Y., Liu, G., & Wei, Y. (2017). P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. *PLOS ONE*, *12*(2), e0172324. https://doi.org/10.1371/journal.pone.0172324

Panigoro, S. S., Kurnia, D., Kurnia, A., Haryono, S. J., & Albar, Z. A. (2020a). ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer. *International Journal of Surgical Oncology*, *2020*, 1–7. https://doi.org/10.1155/2020/7863243

Panigoro, S. S., Kurnia, D., Kurnia, A., Haryono, S. J., & Albar, Z. A. (2020b). ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer. *International Journal of Surgical Oncology*, *2020*, 1–7. https://doi.org/10.1155/2020/7863243

Panigrahi, G., & Ambs, S. (2021). How Comorbidities Shape Cancer Biology and Survival. *Trends in Cancer*, *7*(6), 488–495. https://doi.org/10.1016/j.trecan.2020.12.010

PERABOI. (2020). *Panduan Penatalaksanaan Kanker Payudara di Indonesia Edisi II*. Perhimpunan Ahli Bedah Onkologi Indonesia.

Perou, C. M. (2010). Molecular Stratification of Triple-Negative Breast Cancers. *The Oncologist*, *15*(S5), 39–48. https://doi.org/10.1634/theoncologist.2010-S5-39

Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, Ø., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A.-L., Brown, P. O., & Botstein, D. (2000). Molecular portraits of human breast tumours. *Nature*, *406*(6797), 747–752. https://doi.org/10.1038/35021093

Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015). Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. *Breast Cancer Research and Treatment*, *153*(3), 477–491. https://doi.org/10.1007/s10549-015-3559-0

Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016). Features of triple-negative breast cancer. *Medicine*, *95*(35), e4614. https://doi.org/10.1097/MD.0000000000004614

Pogoda, K., Niwińska, A., Murawska, M., & Pieńkowski, T. (2013). Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Medical Oncology*, *30*(1), 388. https://doi.org/10.1007/s12032-012-0388-4

Prihantono, P., Hatta, M., Binekada, C., Sampepajung, D., Haryasena, H., Nelwan, B., Asadul Islam, A., & Nilawati Usman, A. (2017). Ki-67 Expression by Immunohistochemistry and

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. *Journal of Oncology*, *2017*, 1–8. https://doi.org/10.1155/2017/6209849

Qiu, J., Xue, X., Hu, C., Xu, H., Kou, D., Li, R., & Li, M. (2016). Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. *Journal of Cancer*, *7*(2), 167–173. https://doi.org/10.7150/jca.10944

Ramanan, N., Malik, M., Upneja, S., Farooq, H., Kulkarni, S., Gupta, R., Mathews, J., Nasser, A., Bocicariu, A., Arayan, L., Porter, L., Fifield, B.-A., Luo, R., Brackstone, M., & Hamm, C. (2025). Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis. *Biomedicines*, *13*(5), 1100. https://doi.org/10.3390/biomedicines13051100

Remnant, L., Kochanova, N. Y., Reid, C., Cisneros-Soberanis, F., & Earnshaw, W. C. (2021). The intrinsically disorderly story of Ki-67. *Open Biology*, *11*(8). https://doi.org/10.1098/rsob.210120

Scholzen, T., & Gerdes, J. (2000). The Ki-67 protein: From the known and the unknown. *Journal of Cellular Physiology*, *182*(3), 311–322. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9

Shaker, N., Ding, Q., Wang, Y., & Li, Z. (2022). Low-Grade Invasive Triple Negative Breast Carcinoma. *Journal of Clinical and Translational Pathology*, *000*(000), 000–000. https://doi.org/10.14218/JCTP.2022.00010

Sharma, P. (2016a). Biology and Management of Patients With Triple-Negative Breast Cancer. *The Oncologist*, *21*(9), 1050–1062. https://doi.org/10.1634/theoncologist.2016-0067

Shen, Y., Huang, R., Zhang, Y., Zhu, J., & Li, Y. (2025). Prediction of axillary lymph node metastasis in triple negative breast cancer using MRI radiomics and clinical features. *Scientific Reports*, *15*(1), 21923. https://doi.org/10.1038/s41598-025-08001-6

Shien, T., Tanaka, T., Tanabe, M., Okumura, Y., Masuda, N., Yoshida, A., Arima, N., Komoike, Y., Tanaka, S., Iwase, T., Taguchi, T., Nakatsukasa, K., Inaji, H., & Ishitobi, M. (2017). Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence. *Oncology Letters*, *13*(3), 1071–1077. https://doi.org/10.3892/ol.2016.5538

Singh, D., Roy, N., & Das, S. M. (2020). Epidemiology, Pattern of Recurrence and Survival in Triple-negative Breast Cancer. *Asian Pacific Journal of Cancer Care*, *5*(2), 87–94. https://doi.org/10.31557/apjcc.2020.5.2.87-94

Sinn, H.-P., Schneeweiss, A., Keller, M., Schlombs, K., Laible, M., Seitz, J., Lakis, S., Veltrup, E., Altevogt, P., Eidt, S., Wirtz, R. M., & Marmé, F. (2017). Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. *BMC Cancer*, *17*(1), 124. https://doi.org/10.1186/s12885-017-3111-1

Skjervold, A. H., Pettersen, H. S., Valla, M., Opdahl, S., & Bofin, A. M. (2022). Visual and digital assessment of Ki-67 in breast cancer tissue - a comparison of methods. *Diagnostic Pathology*, *17*(1), 45. https://doi.org/10.1186/s13000-022-01225-4

Sobecki, M., Mrouj, K., Colinge, J., Gerbe, F., Jay, P., Krasinska, L., Dulic, V., & Fisher, D. (2017). Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. *Cancer Research*, *77*(10), 2722–2734. https://doi.org/10.1158/0008-5472.CAN-16-0707

Sopik, V., & Narod, S. A. (2018). The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. *Breast Cancer Research and Treatment*, *170*(3), 647–656. https://doi.org/10.1007/s10549-018-4796-9

Stamatiou, K., & Vagnarelli, P. (2021). Chromosome clustering in mitosis by the nuclear protein Ki-67. *Biochemical Society Transactions*, *49*(6), 2767–2776. https://doi.org/10.1042/BST20210717

Standring S. (2020). *Gray's Anatomy: The Anatomical Basis of Clinical Practice*. Elsevier.

UNIVERSITAS GADJAH MADA
Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Sun, X., & Kaufman, P. D. (2018). Ki-67: more than a proliferation marker. *Chromosoma*, *127*(2), 175–186. https://doi.org/10.1007/s00412-018-0659-8

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Tomita, H., Tanaka, K., Tanaka, T., & Hara, A. (2016). Aldehyde dehydrogenase 1A1 in stem cells and cancer. *Oncotarget*, *7*(10), 11018–11032. https://doi.org/10.18632/oncotarget.6920

Tzikas, A.-K., Nemes, S., & Linderholm, B. K. (2020). A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. *Breast Cancer Research and Treatment*, *182*(3), 643–654. https://doi.org/10.1007/s10549-020-05727-x

Ugras, S., Stempel, M., Patil, S., & Morrow, M. (2014). Estrogen Receptor, Progesterone Receptor, and HER2 Status Predict Lymphovascular Invasion and Lymph Node Involvement. *Annals of Surgical Oncology*, *21*(12), 3780–3786. https://doi.org/10.1245/s10434-014-3851-y

Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005). Proliferation Marker Ki-67 in Early Breast Cancer. *Journal of Clinical Oncology*, *23*(28), 7212–7220. https://doi.org/10.1200/JCO.2005.07.501

Uxa, S., Castillo-Binder, P., Kohler, R., Stangner, K., Müller, G. A., & Engeland, K. (2021). Ki-67 gene expression. *Cell Death & Differentiation*, *28*(12), 3357–3370. https://doi.org/10.1038/s41418-021-00823-x

van Schaik, T., Manzo, S. G., Vouzas, A. E., Liu, N. Q., Teunissen, H., de Wit, E., Gilbert, D. M., & van Steensel, B. (2022). Dynamic chromosomal interactions and control of heterochromatin positioning by Ki-67. *EMBO Reports*, *23*(12). https://doi.org/10.15252/embr.202255782

Vassalli, G. (2019). Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells. *Stem Cells International*, *2019*, 1–15. https://doi.org/10.1155/2019/3904645

Vihervuori, H., Korpinen, K., Autere, T. A., Repo, H., Talvinen, K., & Kronqvist, P. (2022). Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation. *Breast Cancer Research and Treatment*, *196*(3), 471–482. https://doi.org/10.1007/s10549-022-06767-1

Wei, D., Chen, W., Meng, R., Zhao, N., Zhang, X., Liao, D., & Chen, G. (2018). Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients. *Respiratory Research*, *19*(1), 150. https://doi.org/10.1186/s12931-018-0843-7

Wei, Y., Li, Y., Chen, Y., Liu, P., Huang, S., Zhang, Y., Sun, Y., Wu, Z., Hu, M., Wu, Q., Wu, H., Liu, F., She, T., & Ning, Z. (2022). ALDH1: A potential therapeutic target for cancer stem cells in solid tumors. *Frontiers in Oncology*, *12*. https://doi.org/10.3389/fonc.2022.1026278

Wu, Q., Ma, G., Deng, Y., Luo, W., Zhao, Y., Li, W., & Zhou, Q. (2019). Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. *Frontiers in Oncology*, *9*. https://doi.org/10.3389/fonc.2019.01068

Xu, J., Dong, K., Bai, X., Zhang, M., Du, Q., Chen, L., & Yang, J. (2024). GluOC promotes proliferation and metastasis of TNBC through the ROCK1 signaling pathway. *Cancer Cell International*, *24*(1), 263. https://doi.org/10.1186/s12935-024-03445-8

Yan, B., Bai, D.-S., Zhang, C., Qian, J.-J., Jin, S.-J., & Jiang, G.-Q. (2020). Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database. *International Journal of Surgery*, *80*, 94–100. https://doi.org/10.1016/j.ijsu.2020.06.018

Yang, Y., Li, Z., Zhu, Y., Guo, C., Yang, L., & Zhang, J. (2025a). Clinical significance and expression of ALDH1 in triple-negative breast cancer. *Diagnostic Pathology*, *20*(1), 117. https://doi.org/10.1186/s13000-025-01726-y

UNIVERSITAS
GADJAH MADA
**Hubungan Antara Ekspresi ALDH1 Dan ki-67 Pada Triple Negative Breast Cancer Operable Dengan Disease
Free Survival**
erwin parulian pasaribu, Artanto Wahyono; Teguh Aryandono; Paranita Ferronika
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Yao, Y., Chu, Y., Xu, B., Hu, Q., & Song, Q. (2019). Risk factors for distant metastasis of patients with primary triple-negative breast cancer. *Bioscience Reports*, *39*(6). https://doi.org/10.1042/BSR20190288

Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*, *22*(1), 61. https://doi.org/10.1186/s13058-020-01296-5

Young, S., Pilarski, R. T., Donenberg, T., Shapiro, C., Hammond, L. S., Miller, J., Brooks, K. A., Cohen, S., Tenenholz, B., DeSai, D., Zandvakili, I., Royer, R., Li, S., & Narod, S. A. (2009). The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. *BMC Cancer*, *9*(1), 86. https://doi.org/10.1186/1471-2407-9-86

Zanoni, M., Bravaccini, S., Fabbri, F., & Arienti, C. (2022). Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance. *Frontiers in Medicine*, *9*. https://doi.org/10.3389/fmed.2022.795762

Zhai, Z., Zheng, Y., Yao, J., Liu, Y., Ruan, J., Deng, Y., Zhou, L., Zhao, P., Yang, S., Hu, J., We, B., Wu, Y., Zhang, D., Kang, H., & Dai, Z. (2020). Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer. *JAMA Network Open*, *3*(11), e2021881. https://doi.org/10.1001/jamanetworkopen.2020.21881

Zhu, X., Chen, L., Huang, B., Wang, Y., Ji, L., Wu, J., Di, G., Liu, G., Yu, K., Shao, Z., & Wang, Z. (2020a). The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. *Scientific Reports*, *10*(1), 225. https://doi.org/10.1038/s41598-019-57094-3

Zhu, X., Chen, L., Huang, B., Wang, Y., Ji, L., Wu, J., Di, G., Liu, G., Yu, K., Shao, Z., & Wang, Z. (2020b). The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. *Scientific Reports*, *10*(1), 225. https://doi.org/10.1038/s41598-019-57094-3

Zong, Y., Ma, S., Yin, J., Qiao, N., Zhang, D., Niu, Z., Zhao, Y., & Zhou, F. (2025). Clinical significance of ALDH1A1 and Ki67 expression in women with breast carcinoma. *Histology and Histopathology*, *40*(9), 1479–1486. https://doi.org/10.14670/HH-18-880

Zong, Y., Shuang, Yin, J., Qiao, N., Zhang, D., Niu, Z., Zhao, Y., & Zhou, F. (2025). Clinical significance of ALDH1A1 and Ki67 expression in women with breast carcinoma. *Histology and Histopathology*, 18880. https://doi.org/10.14670/hh-18-880